Although some STAT3 inhibitors, such as NSC 74859 (Lin et al., 2009) and LLL12 (Zuo et al., 2015), have been reported to inhibit STAT3 activation in HCC cells, no STAT3 inhibitor has been approved for treating HCC. The gene discussed is STAT3; the disease is hepatocellular carcinoma.